Michael R. Megna net worth and biography

Michael Megna Biography and Net Worth

Group Vice President of Finance and Chief Accounting Officer of Kiniksa Pharmaceuticals

Mike, joined Kiniksa in 2018, has over 20 years of experience in financial management and operations, primarily focused on the life sciences industry. Prior to joining Kiniksa, Mike spent over six years at LFB USA Inc., formerly rEVO Biologics, Inc., in roles of financial and operational leadership, most recently serving as senior vice president of finance and accounting. He played a key role in the financial carve-out of rEVO Biologics to create a focused commercial entity to finance a follow-on indication of the company’s previously approved biologic product, ATryn®. At LFB USA, his most recent responsibilities included financial operations, human resources, information technology, and program management. Prior to LFB USA, he held senior financial management positions at BioSphere Medical, Inc., a publicly traded medical device company. Mike began his career in public accounting, including at PricewaterhouseCoopers, where he worked with a variety of public and private audit clients. He has a Bachelor of Business Administration in accounting from Siena College. Mike is also a Certified Public Accountant.

What is Michael R. Megna's net worth?: The estimated net worth of Michael R. Megna is at least $396,890.81 as of March 1st, 2024. Mr. Megna owns 17,588 shares of Kiniksa Pharmaceuticals stock worth more than $396,891 as of March 14th. This net worth estimate does not reflect any other investments that Mr. Megna may own. Learn More about Michael R. Megna's net worth.
How old is Michael R. Megna?: Mr. Megna is currently 53 years old. There are 5 older executives and no younger executives at Kiniksa Pharmaceuticals. The oldest executive at Kiniksa Pharmaceuticals is Dr. John F. Paolini FACC, M.D., Ph.D., Senior VP & Chief Medical Officer, who is 59 years old. Learn More on Michael R. Megna's age.
How do I contact Michael R. Megna?: The corporate mailing address for Mr. Megna and other Kiniksa Pharmaceuticals executives is CLARENDON HOUSE 2 CHURCH STREET, HAMILTON D0, HM11. Kiniksa Pharmaceuticals can also be reached via phone at (781) 431-9100 and via email at ir@kiniksa.com. Learn More on Michael R. Megna's contact information.
Has Michael R. Megna been buying or selling shares of Kiniksa Pharmaceuticals?: Michael R. Megna has not been actively trading shares of Kiniksa Pharmaceuticals during the past quarter. Most recently, Michael R. Megna sold 9,659 shares of the business's stock in a transaction on Friday, March 1st. The shares were sold at an average price of $21.45, for a transaction totalling $207,185.55. Following the completion of the sale, the chief accounting officer now directly owns 17,588 shares of the company's stock, valued at $377,262.60. Learn More on Michael R. Megna's trading history.
Who are Kiniksa Pharmaceuticals' active insiders?: Kiniksa Pharmaceuticals' insider roster includes Michael Megna (Group Vice President of Finance and Chief Accounting Officer), John Paolini (Executive Vice President, Chief Medical Officer), Sanj Patel (CEO and Chairman of the Board), Mark Ragosa (CFO), and Eben Tessari (https://monarchcasino.com/corporategovernance_boardofdirectors.asp). Learn More on Kiniksa Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Kiniksa Pharmaceuticals?: In the last year, insiders at the sold shares 11 times. They sold a total of 333,156 shares worth more than $8,367,632.36. The most recent insider tranaction occured on February, 10th when COO Eben Tessari sold 14,000 shares worth more than $273,980.00. Insiders at Kiniksa Pharmaceuticals own 54.6% of the company. Learn More about insider trades at Kiniksa Pharmaceuticals.
Information on this page was last updated on 2/10/2025.

Michael R. Megna Insider Trading History at Kiniksa Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/12/2025	Sell	9,051	$22.45	$203,194.95	26,528
3/1/2024	Sell	9,659	$21.45	$207,185.55	17,588
2/28/2024	Sell	5,126	$21.79	$111,695.54	17,588
1/2/2024	Sell	16,670	$19.17	$319,563.90	17,005
12/19/2023	Sell	9,316	$19.13	$178,215.08	17,005

Michael R. Megna Buying and Selling Activity at Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals Company Overview

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.

Today's Range

Now: $22.61

$22.02

$22.86

50 Day Range

MA: $19.95

$18.17

$22.50

2 Week Range

Now: $22.61

$16.56

$28.15

Volume

595,003 shs

Average Volume

407,191 shs

Market Capitalization

$1.64 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.48

Michael Megna Biography and Net Worth

What is Michael R. Megna's net worth?

How old is Michael R. Megna?

How do I contact Michael R. Megna?

Has Michael R. Megna been buying or selling shares of Kiniksa Pharmaceuticals?

Who are Kiniksa Pharmaceuticals' active insiders?

Are insiders buying or selling shares of Kiniksa Pharmaceuticals?